Abstract:This meta-analysis aimed to assess the efficacy and toxicity of extended adjuvant aromatase inhibitors (AIs) in early breast cancer. Seven randomized clinical trials that involved 16,926 patients were selected for analysis. The results showed that extended AI therapy could significantly improve disease-free survival, especially for contralateral breast cancer recurrence. In addition, there were no significant differences between AIs and control for overall survival and serious adverse events. Background: Aromatase inhibitors (AIs) are widely used for early breast cancer, whereas the efficacy and safety of extended AI adjuvant therapy compared with shorter AI therapy, observation, or placebo remains controversial. We conducted a quantitative meta-analysis to summarize available randomized controlled trials (RCTs) regarding the efficacy and safety of extended AI therapy for early breast cancer. Materials and Methods: We systematically searched PubMed, EmBase, and the Cochrane library to select studies published through March 2018. Studies designed as RCTs and that investigated overall survival (OS) or disease-free survival (DFS) for extended AI and shorter AI therapy, observation, or placebo were included. Hazard ratio (HR) and relative risk (RR) with 95% confidence intervals (CIs) were employed to pool analysis according to data type. Results: We identified 7 RCTs that involved 16,926 patients with early breast cancer. The summary HRs indicated that extended treatment with AIs was not associated with OS (HR, 0.95; 95% CI, 0.82-1.10; P = .488), whereas it could significantly improve DFS as compared with shorter AI therapy, observation, or placebo (HR, 0.75; 95% CI, 0.66-0.86; P < .001). Treatment with extended AIs significantly reduced contralateral breast cancer recurrence (RR, 0.46; 95% CI, 0.34-0.64; P < .001), whereas it has no significant effect on distant metastatic recurrence (RR, 0.80; 95% CI, 0.64-1.00; P = .055), and locoregional recurrence (RR, 0.76; 95% CI, 0.53-1.08; P = .127). There were no significant differences between treatment with extended AIs and control for grade 3 or more adverse events. Conclusion: Extended AI therapy could significantly improve DFS, especially for contralateral breast cancer recurrence. There were no significant differences between treatment with AIs and control for OS, distant metastatic and locoregional recurrence, and serious adverse events. (C) 2019 Elsevier Inc. All rights reserved.

Impact of Aromatase Inhibitors Treatment Duration on Coronary Artery Calcification in Postoperative Patients With Breast Cancer

Aromatase Inhibitors and Risk of Cardiovascular Events in Breast Cancer Patients: a Systematic Review and Meta-Analysis

Incidence Of Menopausal Symptoms In Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors

Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer

Extended Adjuvant Therapy with Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.

Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?

Long-term safety of aromatase inhibitors in the treatment of breast cancer

The Impact of Breast Cancer Radiation Therapy Exposure on the Prevalence of Breast Arterial Calcification

Impact of Cardio-Ankle Vascular Index on Future Cancer in Patients With Coronary Artery Disease

Clinical Study of Aromatase Inhibitors in Advanced Breast Cancer

Predictors of recovery of ovarian function during aromatase inhibitor therapy

Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Pharmacogenomics of Aromatase Inhibitors in Postmenopausal Breast Cancer and Additional Mechanisms of Anastrozole Action

Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis

Current and future advances in practice: aromatase inhibitor–induced arthralgia

Abstract 12984: Impact of Cardio-Ankle Vascular Index on New Cancer Diagnosis in Patients With Coronary Artery Disease

Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence

Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis